ADMP Announces Positive Results For Its Dry Powder Inhaler Product; BOTA Commences Dosing In Vapendavir Phase 2b Trial

ADMP announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. BOTA announced it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.